Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin for pediatric CD22-positive relapsed or refractory acute lymphoblastic leukemia
NL-OMON27023Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) and mature B-cell lymphoma (6 arms), sponsored by Erasmus MC. Primary endpoints: Dose-limiting toxicities, Overall response rate and 1 more. Started Jul 2016; status: recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON27023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27023.